Cognizant Extends Gilead Sciences Partnership with AI-Enabled DevOps Focus

  • Cognizant has signed a five-year extension with Gilead Sciences to enhance AI-enabled DevOps capabilities.
  • The agreement focuses on practical AI applications and DevOps improvements for Gilead's technology programs.
  • Cognizant has supported Gilead's IT infrastructure for over a decade, with this deal expanding into AI and DevOps.
  • Gilead's Global CIO Anna Berg Asberg emphasizes the deal's role in strengthening technology foundations for scientific priorities.

This extension underscores the growing importance of AI and DevOps in the biopharmaceutical sector, as companies like Gilead seek to streamline operations and accelerate scientific breakthroughs. The deal highlights Cognizant's strategy of leveraging its AI Builder capabilities to secure long-term partnerships in high-growth industries. The five-year commitment suggests confidence in the scalability of AI-enabled solutions within Gilead's complex technology environment.

AI Integration
How Cognizant's AI tools will impact Gilead's operational efficiency and program execution.
DevOps Scalability
Whether Gilead can sustain improved delivery across its priority technology programs.
Strategic Alignment
The pace at which Cognizant can align its life sciences experience with Gilead's evolving technology needs.